Drugs / immune globulin G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05584631 | Sep 2022 → Dec 2026 expected | chronic inflammatory demyelinating polyradiculoneuropathy, immunodeficiency disease | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | immune globulin G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05584631 ↗ |
| Modality | Protein / enzyme biologic | “immunoglobulin G (IgG)” NCT05584631 ↗ |
| Route | Intravenous | “Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.” NCT05584631 ↗ |